Table 3.

Odds Ratio of Risk of Future HIV Load >20 Copies/mL by Concentration of Tenofovir Diphosphate in DBS at Current Visit in a Subset of 284 Participants with Consecutively Analyzed DBS (N = 452 Paired Assessments)

TFV-DP (fmol/punch)	Paired Assessments, n (%)	OR (95% CI)	P Value	aOR (95% CI)a	P Value
BLQ to <800	57 (13)	4.4 (2.1–9.4)	<.0001	4.5 (2.0–10.1)	.0003
800 to <1650	167 (37)	1.9 (1.1–3.4)	.02	2.2 (1.2–4.3)	.01
≥1650	228 (50)	1	REF	1	REF

Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; BLQ, below limit of quantification; CI, confidence interval; DBS, dried blood spots; HIV, human immunodeficiency virus; OR, odds ratio; REF, reference; TFV-DP, tenofovir diphosphate.

^aAdjusted for age, sex, race, body mass index, estimated glomerular filtration rate, CD4⁺ T-cell count, and antiretroviral therapy class. The OR and aOR between categories BLQ to <800 vs 800 to <1650 fmol/punch were 2.3 (1.2–4.5), P = .02 and 2.0 (0.9–4.3), P = .08, respectively.